Unscheduled Cancer Pain Admissions Costly: Close to $5 Million a Year at M.D. Anderson

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

HOUSTON-Unscheduled hospital admissions for treatment of pain represent a significant cost-$4.7 million annually in a study from The University of Texas M.D. Anderson Cancer Center.

HOUSTON-Unscheduled hospital admissions for treatment of painrepresent a significant cost-$4.7 million annually in a studyfrom The University of Texas M.D. Anderson Cancer Center.

Monica M. Larsen, BA, of the Department of Pharmacoeconomics,who presented the abstract at the 8th World Congress on Pain,said that more effective outpatient pain interventions are thekey to reducing these expensive admissions.

Ms. Larsen and her colleagues reviewed the records of all patientsadmitted through the emergency care unit over a 6-month period.

Of the 1,166 total admissions, 14% were for pain, ranking secondonly to fever (35%). The reasons for the pain admissions werepain management (60%), abdominal pain (24%), chest pain (10%),headache (5%), and back pain (1%).

The mean length of stay for pain admissions was 10.5 days, andthe mean patient charge per admission was $19,000 ($1,800 perday).

Using the hospital-specific cost-to-charge ratio of 0.74, theresearchers determined that the actual hospital cost per admissionfor pain was $14,000 ($1,300 per day). Thus, they were able topredict an annual cost of about $4.7 million for unscheduled painadmissions.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.